Jefferies Starts Medgenics (MDGN) at Buy

September 23, 2016 6:57 AM EDT
Get Alerts MDGN Hot Sheet
Price: $5.12 +0.39%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MDGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies initiates coverage on Medgenics (NYSE: MDGN) with a Buy rating and a price target of $10.00.

Analyst Matthew Andrews commented, "Initiating coverage with a Buy Rating and $10 price target. MDGN-001 is in a Ph. II/III study for the treatment of pediatric/adolescent ADHD with genetic mutations (25% of the U.S. ADHD market; 1.6M patients). We see meaningful upside from current levels with positive Ph. II/III SAGA data in Q4 (November) which replicate its Ph. I(b) “stimulant”-like efficacy profile."

For an analyst ratings summary and ratings history on Medgenics click here. For more ratings news on Medgenics click here.

Shares of Medgenics closed at $5.38 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co

Add Your Comment